Evidence map›Paper›PMID 41659671›Full record

ArticlebioRxiv : the preprint server for biology2026

A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.

Jasmin Coulombe-Huntington, Thierry Bertomeu, Caroline Huard, Andrew Chatr-Aryamontri, Daniel J St-Cyr, María Sánchez-Osuna, David Papadopoli, Karine Normandin, Mohammadjavad Paydar, Shannon McLaughlan and 32 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

Jasmin Coulombe-HuntingtonInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0003-0292-7654
Thierry BertomeuInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-5313-7057
Caroline HuardInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0001-9646-0500
Andrew Chatr-AryamontriInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-1589-9982
Daniel J St-CyrInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0003-2432-6585
María Sánchez-OsunaProgram in Molecular Medicine, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0002-2505-3198
David PapadopoliGerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada.ORCID 0000-0002-1248-1839
Karine NormandinInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.
Mohammadjavad PaydarInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-0569-7017
Shannon McLaughlanDepartment of Biochemistry, McGill University, Montreal, QC, Canada.ORCID 0000-0002-6838-8617
Corinne St-DenisInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0009-0003-3629-9470
Li ZhangInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0009-0001-8476-3536
Henry SayProgram in Molecular Medicine, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0003-1788-1222
Roger PalouProgram in Molecular Medicine, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0001-7674-9358
Chris StarkProgram in Molecular Medicine, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0009-0000-4330-335X
Bobby-Joe BreitkreutzProgram in Molecular Medicine, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0009-0002-7110-0044
Almer M van der SlootThe Québec Artificial Intelligence Institute, Mila, Montréal, QC, Canada.ORCID 0000-0003-0049-2044
Sandhya ManoharDepartment of Molecular Mechanisms of Disease, Universität Zürich, Zurich, Switzerland.ORCID 0000-0002-1322-3954
Hugo LavoieInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0003-0560-2409
Katherine L B BordenInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0003-2188-5074
Brian RaughtPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0001-6145-4776
Damien D'AmoursOttawa Institute of Systems Biology, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.ORCID 0000-0002-2183-9951
Frank SicheriThe Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.ORCID 0000-0002-9824-2117
Alain VerreaultInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-0466-9137
Sylvie MaderInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-6423-627X
Sylvain MelocheInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-6201-7786
Marc TherrienInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0003-2047-7650
Pierre ThibaultInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0001-5993-0331
Brian WilhelmInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0001-9360-3887
Peter B DirksProgram in Developmental, Stem Cell & Cancer Biology, Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0001-5718-6465
John D AitchisonCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Departments of Pediatrics and Biochemistry, University of Washington, WA, USA.ORCID 0000-0002-9153-6497
Elizabeth PattonMRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-2570-0834
Randall W KingDepartment of Cell Biology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7882-8180
Philippe P RouxInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-5962-0250
Guy SauvageauInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-4333-7266
Trang HoangInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0001-7528-9142
Anne MarinierInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-0116-8345
Lea HarringtonDepartment of Biochemistry, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-4977-2744
Benjamin KwokDepartment of Oral Biology, College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, USA.ORCID 0000-0002-3668-7049
Vincent ArchambaultInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-2857-7667
Ivan TopisirovicGerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada.ORCID 0000-0002-5510-9762
Mike TyersProgram in Molecular Medicine, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0002-9713-9994

Funding

BioGRID: An open resource for biological interactions and network analysisR01OD010929 · OD · SINAI HEALTH SYSTEM · PI KARA DOLINSKI, Mike Tyers · 2012 to 2026
$13.9M
Mechanistic Analysis of the Ubiquitin-Proteasome SystemR35GM127032 · NIGMS · HARVARD MEDICAL SCHOOL · PI RANDALL W KING · 2018 to 2026
$4.0M
NIGMS NIH HHS R35 GM127032NIH HHS R01 OD010929
6 · The paper itself

Abstract

To probe drug mechanism of action (MOA) and interrogate the genetic architecture of human cells, we carried out isogenic genome-wide CRISPR/Cas9 knockout screens against 310 diverse drugs, bioactive compounds, and stress conditions. Stringent statistical correction for gene knockout fitness defects yielded a large-scale matrix of >12,000 high confidence chemical-genetic interactions (CGIs). This dataset revealed many previously unappreciated off-target effects for well-characterized compounds and novel MOAs for uncharacterized compounds. The CGI matrix uncovered dense genetic modules that yielded new biological insights into phospholipidosis, mitotic regulation, metabolism, the DNA damage response, and mTOR signaling. The dataset allowed identification of multi-drug sensitization and resistance mechanisms, inference of gene function, elaboration of cross-process connectivity, evaluation of the cell type specificity of CGIs, prediction of chemical synergism, and extensive annotation of understudied genes. This resource provides a map of the genetic landscape in human cells and a framework to help guide drug discovery.

Indexed as

chemical-genetic interactionchemical synergychemogenomic profileCRISPR/Cas9DNA damage responsedrug mechanismgene functionmitosismTORphospholipidosis

Identifiers

PMID41659671
PMCPMC12873861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.